CARLSBAD, Calif. , July 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference on Wednesday, July 20, 2022 .
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
– Positive data from a Phase 2 study of IONIS-FB-L Rx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif. , July 11, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
– Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B – Phase 3 clinical study evaluating b epirovirsen as a monotherapy is anticipated to start in the first half of 2023 – GSK to
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
– Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN – Eplontersen demonstrated a favorable safety profile – Ionis and AstraZeneca expect to file a New Drug Application this year CARLSBAD, Calif.
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
CARLSBAD, Calif. , June 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an